ArticleFrontiers in oncology2026

Case Report: Trastuzumab deruxtecan combined with fulvestrant in a patient with HR+/HER2-low metastatic breast cancer.

Jiaying Chai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.